Načítá se...
Proteolysis‐targeting chimeras in drug development: A safety perspective
Proteolysis‐targeting chimeras are a new drug modality that exploits the endogenous ubiquitin proteasome system to degrade a protein of interest for therapeutic benefit. As the first‐generation of proteolysis‐targeting chimeras have now entered clinical trials for oncology indications, it is timely...
Uloženo v:
| Vydáno v: | Br J Pharmacol |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7070175/ https://ncbi.nlm.nih.gov/pubmed/32022252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15014 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|